Another Divestment By Takeda, To China’s Hasten For $322m
Executive Summary
Japanese major sheds further non-core assets as it continues to focus on innovation and pay down debt following the Shire acquisition.
You may also be interested in...
Hasten, Orbital Raise 2023’s Biggest Venture Capital Rounds Days Apart
Hasten brought in $315m, and Orbital garnered $270m, but while multiple venture firms have raised large new funds, Q1 saw the lowest amount of biopharma VC fundraising in a single quarter since 2019.
Deal Watch: GSK Makes $85m Wager On Surface’s Preclinical NK Cell Therapy
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
Novartis Xiidra Buy Looks Even Pricier With File Pulled In EU
A year after inking a multi-billion dollar deal to get hold of the Takeda eye drop, Novartis has given up on getting approval for Xiidra in Europe with the EMA unconvinced about the therapy's efficacy.